MarketPulse

cash deal

3 articles
The Motley FoolThe Motley Fool··Eric Volkman

Neurocrine Snaps Up Soleno for $2.9B, Betting Big on Rare Disease Drug

Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9B in all-cash deal, paying $53/share—a 34% premium driven by Soleno's FDA-approved Vykat XR for Prader-Willi Syndrome.
SLNONBIXacquisitionFDA approval
BenzingaBenzinga··Lekha Gupta

Veris Residential To Be Acquired by Affinius Capital Consortium for $3.4B

Affinius Capital consortium to acquire multifamily REIT Veris Residential for $3.4B, offering shareholders $19/share—a 23.2% premium.
VREacquisitionshareholder value
BenzingaBenzinga··Akanksha Bakshi

Tidewater Expands Brazil Operations With $500M Acquisition

Tidewater acquires Brazilian offshore companies for $500M, expanding its vessel fleet from 6 to 28 units in the region and strengthening its global presence.
TDWacquisitionM&A